Last updated on March 2018

BAROSTIM THERAPY in Heart Failure With Reduced Ejection Fraction


Brief description of study

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Clinical Study Identifier: NCT02880618

Contact Investigators or Research Sites near you

Start Over

Christian Butter

Immanuel Klinikum Bernau
Bernau, Germany
  Connect »